Praxis Precision Medicines to Participate in Upcoming Conferences

BOSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in three upcoming investor conferences: About Praxis The Company will be available for one-on-one meetings during all events. Interested investors should contact their ...